Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019

January 18, 2020 at 6:13 pm

MMWR. January 10, 2020 V.69 N.1 P.6-9.

Summary

What is already known about this topic?

Candida auris is an emerging yeast that is often drug-resistant.

What is added by this report?

Three chronically ill patients in New York were identified as having pan-resistant C. auris after receipt of antifungal medications. No transmission of the pan-resistant isolates was found in patient contacts or the facility environments.

What are the implications for public health practice?

Three years after the first identification of C. auris in New York, pan-resistant isolates remain rare. Continued surveillance for C. auris, prudent antifungal use, and susceptibility testing for all C. auris clinical isolates (especially after patients have been treated with antifungal drugs) are needed.

FULL TEXT

https://www.cdc.gov/mmwr/volumes/69/wr/mm6901a2.htm

PDF

https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6901a2-H.pdf

Entry filed under: Antimicoticos, BIOFILM - BIOPELICULAS, Biología Molecular, BIOMARCADORES, Epidemiología, Health Care-Associated Infections, Infecciones emergentes, Infecciones micoticas, Infecciones nosocomiales, Metodos diagnosticos, Prevencion y Control de Infecciones, REPORTS, Sepsis, Update.

2018 recommendations for the management of community acquired pneumonia. From contamination to infective endocarditis—a population-based retrospective study of Corynebacterium isolated from blood cultures.


Calendar

January 2020
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Most Recent Posts


%d bloggers like this: